Tracy Johnson, NP
Family · Fort Wayne, INNPI 1518046002
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,939 of the $67,629 with a category attached, or 78.3%. Teva Pharmaceuticals USA, Inc. accounts for 97.1% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $45,970, more than ten times the $127 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $221.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$66K
- Neurocrine Biosciences, Inc.$587
- E.r. Squibb & Sons, L.L.C.$442
- Otsuka America Pharmaceutical, Inc.$269
- Acadia Pharmaceuticals Inc$156
- Jazz Pharmaceuticals Inc.$151
- plus $372 from 6 others
What the payments were for
- Consulting fees$1,2302%
- Speaking & faculty fees$52,93978%
- Travel & lodging$5,6868%
- Food & beverage$7,40011%
- Education$3741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 229 | $65,652 |
| Neurocrine Biosciences, Inc. | 15 | $587 |
| E.r. Squibb & Sons, L.L.C. | 31 | $442 |
| Otsuka America Pharmaceutical, Inc. | 5 | $269 |
| Acadia Pharmaceuticals Inc | 7 | $156 |
| Jazz Pharmaceuticals Inc. | 2 | $151 |
| Johnson & Johnson | 1 | $142 |
| Alkermes, Inc. | 11 | $136 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Inari Medical, Inc. | 1 | $25 |
| Boston Scientific | 1 | $18 |
| Exact Sciences | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$61,224
- AUSTEDO$484
- INGREZZA$354
- UZEDY$238
- Epidiolex$143
- INVEGA SUSTENNA$142
- ABILIFY ASIMTUFII$121
- ABILIFY MAINTENA$121
- NUPLAZID$116
- REXULTI$113
How this compares
$67,629 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 126 | $1,015,780 |
| AustedoDeutetrabenazine | 84 | $554,131 |
| IngrezzaValbenazine Tosylate | 39 | $329,776 |
| NuplazidPimavanserin Tartrate | 63 | $263,044 |
| Invega SustennaPaliperidone Palmitate | 84 | $244,190 |
| RexultiBrexpiprazole | 275 | $164,458 |
| Abilify MaintenaAripiprazole | 55 | $161,621 |
| VraylarCariprazine Hcl | 136 | $95,223 |
| Clozapine | 1,258 | $94,228 |
| Aripiprazole | 781 | $77,216 |
| Paliperidone ErPaliperidone | 96 | $49,074 |
| NuedextaDextromethorphan Hbr/Quinidine | 57 | $48,414 |
| Ziprasidone Hcl | 562 | $41,025 |
| TrintellixVortioxetine Hydrobromide | 160 | $40,857 |
| FanaptIloperidone | 32 | $32,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Loxapine | $65,652 | $1,579,809426 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $587 | $329,77639 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $269 | $326,080330 claims |
| Acadia Pharmaceuticals IncNuplazid | $156 | $263,04463 claims |
| Johnson & JohnsonInvega Sustenna | $142 | $244,19084 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.